Last reviewed · How we verify
NCT06846827: OYSCOG
Cognitive, Mood, Anti-Inflammatory and Metabolic Effects of Chronic Oyster Mushroom Intervention in Older Adults
NA trial testing Oyster mushroom in Cognitive Change in 80 participants. Completed in 3 July 2024.
3 July 2024
Quick facts
| Lead sponsor | University of Reading |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 80 |
| Start date | 1 October 2023 |
| Primary completion | 3 July 2024 |
| Estimated completion | 3 July 2024 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Oyster mushroom — full drug profile →
- Maltodextrin (MALTODEXTRIN) — full drug profile →
Conditions studied
- Cognitive Change — all drugs for Cognitive Change →
- Mood — all drugs for Mood →
- Metabolism — all drugs for Metabolism →
- Inflammatory Response — all drugs for Inflammatory Response →
Sponsor
University of Reading
Who can join
Adults 60 to 80, any sex, with Cognitive Change or Mood. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Pleurotus oyster species is a common edible mushroom rich in phytochemicals such as proteins, phenolic compounds, dietary fibre and is also particularly rich in ergothioneine, a bioactive known for its neurocognitive benefits. Current research suggests that a mushroom-rich diet may be associated with a lower incidence of age-related neurological disorders, as well as an improvement in the domains of memory and mood. This randomized double-blind parallel trial investigates the chronic effect (12-weeks) of the equivalent 1 portion of ergothioneine-rich Pleurotus oyster mushrooms (in freeze-dried powdered form), consumed 4 times per week, on cognition and mood, with examination of the potential inflammatory, metabolic, and neurological related mechanisms that may underlie these effects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06846827
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Oyster mushroom
Trials testing the same drug.
- NCT04989972 — Assessing the Efficacy of Micro-dosed Psilocybin on Reducing Anxiety & Depression Levels in Adults · Phase 2 · withdrawn
Other recruiting trials for Cognitive Change
Currently open trials in the same condition.
- NCT07147894 — Executive Function Training for Children and Adolescents · NA · recruiting
- NCT07383324 — Heat Stress in Individuals With Schizophrenia · NA · recruiting
- NCT07261202 — Impact of Indoor Overheating on Physiological Strain in Children · NA · recruiting
- NCT07267598 — Suitability of a 26 °C Indoor Environment for Mitigating Heat Strain in Young Adults · NA · recruiting
- NCT07054723 — Surviving Daily Life · recruiting
Other University of Reading trials
Trials by the same sponsor.
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07401212 — GUTLINK4KIDS Intervention · NA · recruiting
- NCT07006909 — Hair Isotope Analysis for Early Cancer Detection · not yet recruiting
- NCT06832488 — Food Texture, Eating Rate and Food Intake in Care Home Older Adults. · NA · completed
- NCT07056634 — The Effects of Nature-Based Activity vs. Indoor Exercise on Cognition, Psychological, and Physiological Health · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06846827 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Reading
- Last refreshed: 4 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06846827.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing